63 results about "Nitroglycerol" patented technology

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and / or no-reflow phenomena and / or ischemia-reperfusion injury by administration of agent(s) modulating and / or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb / IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.

The invention discloses a detecting method for accurate risk early warning and accurate drug use of cardiovascular and cerebrovascular diseases and a specific primer. The invention provides a specific primer for detecting SNP site of drug resistance of the cardiovascular and cerebrovascular diseases, which comprises a primer group 1 and a primer group 2; the primer group 1 is composed of primer pair 1-primer pair 13; a primer group 2 is composed of single stranded extended primer 1- single stranded extended primer 13; the method can efficiently detect and complete the accurate early warning of the attack of the cardiovascular and cerebrovascular diseases and the accurate drug use after being attacked, namely, four kinds of cardiovascular and cerebrovascular disease early warning with huge health risk and accurate drug use of four clinical common drugs (aspirin, nitroglycerin, warfarin, and clopidogrel) for prevention and treatment of cardiovascular and cerebrovascular diseases.

The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and / or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.

A method and special-purpose primers used for detecting aspirin and nitroglycerin accurate administration are provided. The special-purpose primers for detecting aspirin and nitroglycerin drug resistance SNP loci are provided and include a primer group 1 and a primer group 2. The primer group 1 includes a primer pair 1, a primer pair 2, a primer pair 3 and a primer pair 4. The primer group 2 includes a single-chain extension primer 1, a single-chain extension primer 2, a single-chain extension primer 3 and a single-chain extension primer 4. An experiment proves that detection of a plurality of SNP loci related to aspirin and nitroglycerin drug resistance is completed efficiently by a one-time experiment, and the one-time experiment can complete aspirin and nitroglycerin accurate administration gene detection, thus reducing the experiment cost. The method and the primers have high application value for directing clinical accurate administration of aspirin and nitroglycerin and are suitable for popularization and application.

Application of oxymatrine injection in antianginal drugs is characterized in that the oxymatrine injection is intravenous fluid prepared by diluting oxymatrine 2 mg / ml with 100 ml of 5% glucose; sitting administration is adopted that is referred to: seat height is adjusted through a lifting mechanism such that the forearm of one upper arm of a patient to take injection is on the same plane with the heart. The oxymatrine injection is the intravenous fluid prepared by diluting oxymatrine 2 mg / ml with 100 ml of 5% glucose; the sitting administration is adopted. The curative effect is 10% higher than that of a control group of nitroglycerin and isosorbide dinitrate.

The invention discloses an application of roxadustat in a medicine for treating migraine and the medicine containing the roxadustat, and relates to the technical field of medicines, wherein the migraine is chronic migraine. The used roxadustat can significantly inhibit nitroglycerin-induced pain sensitivity related to mouse migraine and improve the central sensitization state of the trigeminal nerve spine tail nucleus part, the new application of the roxadustat in the aspect of migraine resistance can expand the research of the roxadustat in the field of medicine, and a new theoretical direction is provided for clinical application.

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx / Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.

The invention relates to a green preparation method of nitroglycerin. The present invention is based on the micro-reactor of Nobel Explosives Company, according to the specific process of the continuous production of raw materials and preparations of nitroglycerin, through arduous innovation, achieved unexpected achievements in the continuous production of green preparations of nitroglycerin The progress has achieved green, safe and risk-free synthesis in the preparation of key APIs, and the subsequent integrated production of combined APIs and nitroglycerin preparations. This process is the first in China and is encouraged by global regulatory authorities. It is the general trend of drug production. .

The invention discloses a traditional Chinese medicine exercise therapy based on a heart rehabilitation unit, and relates to the technical field of chronic disease rehabilitation. The traditional Chinese medicine exercise therapy comprises the following steps: Step 1, treating a coronary heart disease stable angina pectoris patient meeting an inclusion standard by adopting a prospective randomized controlled study; Step 2, performing intervention treatment for 12 weeks by adopting medicine standardized treatment and eight-section brocade treatment; Step 3, taking the twelfth week of treatment as a curative effect evaluation point, adopting a traditional Chinese medicine eight-section brocade intervention method, poking and pressing the acupoint of Jiquan, beating and pressing the acupoint of heart meridian and the acupoint of pericardium meridian, and observing the life quality curative effect and the angina pectoris curative effect; Step 4, performing cardiopulmonary exercise assessment, and adopting a walking experiment; and Step 5, after the patient gets out of the group, carrying out a follow-up visit on the patient once every month. During heart rehabilitation treatment, conventional western medicine standardized treatment is combined with eight-section brocade health preserving exercise and beating and pressing of the acupoint of heart meridian and the acupoint of pericardium meridian, and the traditional Chinese medicine symptom integral, the angina pectoris curative effect, the nitroglycerin stopping and reducing rate, the exercise cardiopulmonary function and the life quality of the patient are improved.

The invention discloses a multifunctional puncture treatment patch medical product which is a bagged patch. A patch block A and a patch block B which are different in treatment effect are packaged in each patch bag, and each patch block is formed by bonding a top patch layer, a middle patch layer and a bottom patch layer which are different in function into a whole. The patch bottom is a breathable layer, the middle is a treatment layer, and the top is an isolation protection layer. The patch is characterized in that the patch A has a treatment effec formed by a medicament formed by uniformly mixing 20mg-30mg of lidocaine, 25mg of nitroglycerin and 1.5 ml of peppermint oil is pasted and covered on a medicine liner in the middle of the patch A; lidocaine is used for anesthetizing and relieving pain, nitroglycerin is used for expanding superficial vessels, and peppermint oil is used for promoting epidermal absorption of the medicine; nitroglycerin is matched with peppermint oil to improve the one-time success rate of vascular puncture; lidocaine enters subcutaneous anesthesia in advance along with nitroglycerin, so that pain during puncture is relieved. And a gelatin sponge block which adsorbs 0.2 ml of 0.25% chloramphenicol liquid is adhered to a liner in the middle of the patch B, so that common symptoms such as errhysis, vascular drug exosmosis and local hypoplasia, inflammation, redness and swelling are eliminated. The invention has the advantages of simple operation, practical method, obvious medical effect and convenient use.